Renal and extrarenal considerations in high-dose mannitol therapy

Area of Science:

• Nephrology
• Critical Care Medicine
• Pharmacology

Background:

• High-dose mannitol is used for cerebral edema.
• Mannitol administration alters extracellular fluid (ECF) volume, osmolality, and composition.
• These alterations can lead to adverse events like renal failure and cardiac decompensation.

Purpose of the Study:

• To elucidate the mechanisms by which patient-specific factors influence ECF changes during mannitol therapy.
• To demonstrate how to predict the magnitude of these ECF changes before treatment.
• To minimize the risk of adverse outcomes associated with mannitol administration.

Main Methods:

• Analysis of patient factors influencing ECF volume, osmolality, and composition.
• Development of predictive models for mannitol-induced ECF changes.
• Correlation of predicted ECF changes with clinical outcomes.

Main Results:

• Patient factors such as body habitus, age, total body water, baseline plasma sodium, and osmolality significantly impact ECF changes.
• The presence of edema or ascites further modifies mannitol's effects.
• Predictive methods were developed to estimate the extent of ECF alterations and mannitol excretion rates.

Conclusions:

• Understanding individual patient variables is crucial for safe mannitol administration.
• Predictive modeling can guide therapeutic decisions and mitigate risks.
• Personalized approaches to mannitol therapy can prevent serious complications.